# Medical Question & Answer

**Sample ID**: e7b56661-7ce3-4eff-8b43-9de5a0e38a2b
**Dataset Index**: 4763

---

## Question

How is pulmonary fibrosis diagnosed?

---

## Answer

> Let's see… What do we have here? The user is asking how pulmonary fibrosis is diagnosed, with emphasis on idiopathic pulmonary fibrosis (IPF). Let's break this down step-by-step. First, I need to think about how to frame the initial clinical suspicion and baseline evaluation. Then, I should verify the systematic exclusion of secondary causes. Next, I will review HRCT acquisition and pattern categorization. After that, I need to decide when tissue sampling is appropriate, including BAL and biopsy. I will then integrate histopathology and the role of transbronchial lung cryobiopsy. Finally, I should ensure multidisciplinary discussion, assign diagnostic confidence, and consider emerging tools like genomic classifiers, while double-checking that each step aligns with major guidelines and key studies [^112PERpW] [^111cvzSR] [^1144VC7o].

> Let me first confirm the clinical triggers that should raise suspicion for IPF or fibrotic ILD. Patients commonly present with progressive exertional dyspnea and nonproductive cough, often in older adults, with exam findings of bibasilar inspiratory crackles; these features, together with imaging that shows bilateral fibrosis, should prompt a structured ILD evaluation, including pulmonary function testing for restriction and reduced DLCO, and early referral to an ILD-capable team to avoid delays in diagnosis and treatment initiation [^111yQ7Hm] [^1113RatU] [^114HoiS8].

> I need to ensure secondary causes are systematically excluded before considering an idiopathic label. Hold on, I should verify that comprehensive exposure and medication histories are explicitly recommended, and that serologies for connective tissue disease are obtained; yes, the 2018 ATS/ERS/JRS/ALAT guideline makes both points clear, and the 2011 statement reiterates exclusion of environmental, drug, and CTD causes as a foundational step in the diagnostic algorithm [^113U9XXW] [^1178bTX6] [^116fgYr6].

> Next, I will examine HRCT acquisition because technical quality directly impacts diagnostic accuracy. Chest CT should be performed with a high-resolution technique (slice thickness ≤ 1.5 mm) and a high-resolution reconstruction algorithm, with careful comparison against prior studies to assess progression and complications; early identification is prioritized due to the progressive nature of fibrosis and implications for antifibrotic therapy timing [^114qtsha] [^114fGbpw] [^113PdceK]. Wait, I initially thought the 2022 ESC/ERS pulmonary hypertension guideline confirmed HRCT as the primary modality for fibrosis evaluation, but that document focuses on PH assessment in lung disease rather than defining HRCT technique for ILD; the appropriate support for HRCT technique and primacy here comes from radiology practice recommendations and ATS/ERS IPF guidance, not PH guidelines [^111hs38H] [^114qtsha] [^1144VC7o].

> Now I should review HRCT pattern categorization, because this often determines whether tissue is needed. A definite UIP pattern requires subpleural and basal predominance with honeycombing and traction bronchiectasis/bronchiolectasis and no features suggesting an alternative diagnosis; when definite UIP is present in the right clinical context, a diagnosis of IPF can be made without surgical lung biopsy per ATS/ERS/JRS/ALAT and Fleischner recommendations [^111WQgqx] [^1144VC7o] [^111cvzSR].

> For probable UIP, I need to be careful not to jump to conclusions. The Fleischner Society allows a confident IPF diagnosis without biopsy in select contexts, whereas the 2018 ATS/ERS/JRS/ALAT guideline gives a conditional recommendation to consider surgical lung biopsy after multidisciplinary discussion; importantly, probable UIP on CT shows high specificity for histopathologic UIP but a modest PPV, and 2022 guideline updates considered but ultimately did not merge the UIP and probable UIP categories due to variability across settings and potential survival differences; also, I should double-check that "conditional" is not misread as "mandatory" for biopsy in probable UIP, as has been clarified subsequently [^111cvzSR] [^112PERpW] [^112PERpW] [^114fgch3] [^115Jtz5k].

> If the CT pattern is indeterminate or suggests an alternative diagnosis, I should confirm next steps. Conditional recommendations support BAL and surgical lung biopsy to clarify etiology in those settings, while no recommendation was made in 2018 for or against conventional transbronchial biopsy or cryobiopsy due to insufficient evidence at that time; the decision should follow an MDD that integrates clinical pretest probability, patient risk, and local expertise [^112PERpW].

> Let me now examine the role of BAL, being careful not to overstate its diagnostic power. BAL has limited standalone value in IPF, where elevated neutrophils and eosinophils may be seen but are not diagnostic; BAL is most useful when infection, malignancy, or acute exacerbation is suspected, and in non-definite UIP patterns where cellular analysis may support alternative diagnoses such as HP when lymphocytosis is ≥ 30%; importantly, BAL cellular analysis should be avoided in definite UIP on HRCT, but considered for probable UIP, indeterminate, or alternative patterns after MDD [^112gBJ4G] [^112Udran] [^116UsWhr] [^113f7aMQ]. Hmm, wait a minute, I initially cited the BAL review with an incorrect identifier; I should correct that the appropriate source is 418c38c1, not 418c38f1, to ensure accurate attribution [^112gBJ4G].

> I will now examine histopathology when tissue is obtained, because defining UIP pathologically anchors the diagnosis. UIP on SLB is characterized by patchy dense fibrosis with architectural distortion and honeycombing, subpleural/paraseptal predominance, fibroblast foci, and absence of features suggesting another diagnosis; when CT is definite UIP, the specificity for histopathologic UIP approaches 97%, supporting noninvasive diagnosis, while TBLC can demonstrate probable UIP but may undersample subpleural regions and complicate exclusion of alternative processes [^112uHc3D] [^113bETkA]. Hold on, I should verify that TBLC tends to yield probable rather than definite UIP and that combining morphologic features without alternative findings can suffice for a probable UIP designation in TBLC specimens; yes, that is consistent with the 2022 update's discussion of TBLC limitations and utility within MDD [^112uHc3D].

> Next, I should review multidisciplinary discussion, because integration across domains is essential. MDD among pulmonology, radiology, and pathology improves diagnostic accuracy and is explicitly recommended in the 2011 and 2018 ATS/ERS/JRS/ALAT documents, with data suggesting better diagnostic agreement and accuracy when decisions are made by core expert groups rather than isolated centers [^113abwYg] [^112PERpW] [^113mypiN].

> I need to assign diagnostic confidence after synthesizing all data, and I should confirm the categories and their implications. Definite IPF requires exclusion of secondary causes plus either a definite UIP pattern on HRCT or histopathology; probable IPF applies when probable UIP is present without an alternative diagnosis; a working diagnosis is appropriate when tissue is unavailable but clinical-radiologic features and disease behavior strongly suggest IPF, with mandated periodic re-evaluation; importantly, a sizable fraction of patients historically remained unclassifiable under the 2011 framework, underscoring the value of MDD and iterative reassessment and the real-world use of antifibrotics at high diagnostic likelihood without SLB in many cases [^111cvzSR] [^114j8Fmq] [^111jWdgZ].

> Let me consider ancillary and emerging diagnostic tools that can refine confidence when tissue is limited. Genomic classifier testing on transbronchial forceps biopsy specimens demonstrates pooled sensitivity and specificity of approximately 68% and 92% for identifying UIP, and can increase diagnostic agreement and confidence in MDD; use should be individualized, balancing the consequences of misclassification and the local availability of expertise [^116M2aHh]. But wait, I should verify that these data apply to ILD of undetermined type undergoing forceps biopsy rather than to all-comers with ILD; that is correct per the 2022 guideline question framing and meta-analysis [^116M2aHh].

> Before concluding, I should re-emphasize the forward flow of the algorithm to avoid missteps. Start with clinical suspicion and function testing, exclude secondary causes with exposure and medication histories plus CTD serologies, acquire high-quality HRCT and categorize the pattern, decide on BAL and biopsy selectively based on CT pattern and MDD, integrate pathology when obtained, and finalize diagnostic confidence with plans for reassessment if a working diagnosis is assigned; throughout, prioritize timely diagnosis given the progressive nature of fibrosis and the need to introduce antifibrotic therapy in appropriate patients without undue delay [^113U9XXW] [^1178bTX6] [^114qtsha] [^113PdceK] [^111cvzSR] [^112PERpW].

> Finally, I should double-check that any earlier ambiguities have been corrected. I initially over-attributed HRCT primacy to ESC/ERS PH guidance and have now anchored HRCT technique and diagnostic role to radiology and ATS/ERS sources; I also corrected the BAL reference identifier; maintaining this self-audit aligns the reasoning with current guideline-concordant practice and preserves transparency in areas where recommendations are conditional and contextual, especially around probable UIP and the use of BAL, SLB, and TBLC within MDD [^1144VC7o] [^114qtsha] [^114fGbpw] [^115Jtz5k] [^112gBJ4G].

---

The diagnosis of pulmonary fibrosis relies on a **multidisciplinary approach** integrating clinical assessment, HRCT, and selective histopathology, with HRCT as the central noninvasive test [^113abwYg] [^1144VC7o] [^114fGbpw] [^111cvzSR]. A **UIP pattern on HRCT** allows confident diagnosis of IPF without biopsy [^111cvzSR], whereas probable or indeterminate patterns [^114fGbpw] require multidisciplinary discussion and may require biopsy [^113bETkA]. BAL is reserved for cases with probable or indeterminate UIP [^113f7aMQ] to exclude alternative diagnoses [^112Udran], and serologic testing helps rule out connective tissue disease [^1178bTX6]. Early, accurate diagnosis enables timely antifibrotic therapy and improves outcomes [^111KDKff] [^114qtsha].

---

## Clinical evaluation

History and physical examination should include a detailed review of **medications and environmental exposures** [^113U9XXW] to exclude known causes of ILD [^116fgYr6]. Common symptoms include progressive dyspnea, dry cough, and bibasilar inspiratory crackles [^112MQjPa]. Pulmonary function tests (PFTs) typically reveal a **restrictive ventilatory defect** [^116KddEp] with reduced forced vital capacity (FVC) and diffusing capacity for carbon monoxide (DLCO) [^113sj3zJ].

---

## Imaging studies

High-resolution computed tomography (HRCT) is the **cornerstone** [^111cvzSR] of pulmonary fibrosis diagnosis, providing detailed imaging of the lung parenchyma and enabling identification of characteristic patterns [^1144VC7o].

- **UIP pattern**: Subpleural, basal-predominant reticulation, honeycombing, and traction bronchiectasis [^111WQgqx]. A definite UIP pattern on HRCT [^111cvzSR] allows a confident diagnosis of IPF without biopsy [^114fGbpw].

- **Probable UIP pattern**: Similar to UIP but without honeycombing. Requires multidisciplinary discussion and may necessitate biopsy [^114fGbpw] [^114fgch3].

- **Indeterminate pattern**: Non-specific findings requiring further evaluation and often biopsy [^114fGbpw] [^111cvzSR].

- **Alternative diagnosis**: Features suggesting other ILDs, such as hypersensitivity pneumonitis or sarcoidosis [^114fGbpw] [^112wy7iA].

---

## Histopathological examination

Histopathological analysis is **essential** [^115UTCMT] when imaging findings are inconclusive or to exclude alternative diagnoses.

- **UIP pattern**: Patchy dense fibrosis with architectural distortion, fibroblast foci, and honeycombing [^112uHc3D]. Absence of features suggesting alternative diagnoses [^114SnhKW].

- **Probable UIP**: Similar features but lacking some definitive characteristics of UIP [^115UTCMT] [^112uHc3D].

- **Indeterminate**: Non-specific fibrosis requiring further clinical correlation [^115UTCMT] [^112uHc3D].

- **Alternative diagnosis**: Features suggesting other ILDs, such as NSIP or hypersensitivity pneumonitis [^114SnhKW] [^112uHc3D].

---

## Role of bronchoalveolar lavage (BAL)

BAL is **useful** [^112gBJ4G] in specific clinical scenarios, particularly when alternative diagnoses such as hypersensitivity pneumonitis or infection are suspected. **Indications** [^113f7aMQ] include probable UIP, indeterminate UIP, or an alternative diagnosis on HRCT [^112Udran], whereas **contraindications** include a definite UIP pattern on HRCT [^116UsWhr].

---

## Serological testing

Serological testing is **recommended** [^1178bTX6] to exclude connective tissue diseases as potential causes of ILD.

---

## Multidisciplinary discussion (MDD)

MDD involving pulmonologists, radiologists, and pathologists experienced in ILD diagnosis is **strongly recommended** to improve diagnostic accuracy and confidence [^113abwYg] [^111cvzSR].

---

## Diagnostic criteria for idiopathic pulmonary fibrosis (IPF)

The diagnosis of IPF requires exclusion of **other known causes** of ILD (environmental exposures, connective tissue disease, drug toxicity) [^116fgYr6], and the presence of a UIP pattern on HRCT or specific combinations of HRCT and surgical lung biopsy findings [^116fgYr6] [^111cvzSR].

---

## Challenges and limitations

- **Diagnostic delay**: Nonspecific symptoms and lack of awareness among primary care physicians contribute to delayed diagnosis [^113hMema] [^115GQ9Kt].

- **Interobserver variability**: Variability in HRCT and histopathology interpretation [^113bETkA] can affect diagnostic accuracy [^111WQgqx].

- **Invasive procedures**: Surgical lung biopsy [^112mQBaa] carries risks, particularly in patients with advanced disease or comorbidities [^113mypiN].

---

## Emerging diagnostic tools

Genomic classifier testing is an emerging tool [^112uHc3D] with moderate sensitivity and high specificity for **UIP pattern identification** [^116M2aHh]. Artificial intelligence (AI) has the potential to improve **diagnostic accuracy** and reduce interobserver variability in HRCT interpretation [^112wy7iA].

---

The diagnosis of pulmonary fibrosis requires a **multidisciplinary approach** integrating clinical evaluation, HRCT imaging, histopathological examination, BAL, and serological testing [^111cvzSR]. Early and accurate diagnosis is **essential** for timely initiation of antifibrotic therapy and improved patient outcomes [^112MQjPa].

---

## References

### ESR essentials: imaging in fibrotic lung diseases-practice recommendations by the European Society of Thoracic Imaging [^113PdceK]. European Radiology (2025). Low credibility.

Patients with clinico-functional suspicion of pulmonary fibrosis, as well as those at high risk due to predisposing diseases or family history, should undergo a chest CT with high-resolution technique to identify early signs of lung fibrosis. Fibrotic lung diseases may show progressive behavior, leading to reduced survival; thus, early diagnosis is crucial to granting prompt antifibrotic treatment. Radiologists have a pivotal role not only in the early identification and non-invasive diagnosis of fibrosis but also in the evaluation of disease progression and complications. Interdisciplinary cooperation with pulmonologists, rheumatologists, and pathologists is mandatory for accurate patient management.

---

### An official ATS/ERS/JRS/ALAT statement: Idiopathic pulmonary fibrosis: Evidence-based guidelines for diagnosis and management [^1177XteZ]. American Journal of Respiratory and Critical Care Medicine (2011). High credibility.

Regarding medical management for idiopathic pulmonary fibrosis, more specifically with respect to acid-reducing therapy, ALAT/ATS/ERS/JRS 2011 guidelines recommend considering initiating treatment for asymptomatic gastroesophageal reflux in the majority of patients with IPF.

---

### Therapeutic intervention: Assessing the role of the international consensus guidelines [^113fhaZh]. Chest (2005). Low credibility.

Idiopathic pulmonary fibrosis (IPF) is a progressive, fatal lung disorder of unknown etiology. The consensus statement released by the American Thoracic Society and European Respiratory Society has provided guidelines for the diagnosis, evaluation, and management of patients with IPF. These guidelines suggest the use of conventional treatment options, including therapy with corticosteroids and immunosuppressive agents. The guidelines statement acknowledged the fact that there is little good-quality evidence to support the safety and efficacy of such therapies in patients with IPF. The statement was published in 2000 and was based on an extensive review of the literature up to and including December 1998. The goal of this review is to reexamine the treatment recommendations of the guidelines statement in the context of data that has since become available.

---

### Overview of pulmonary fibrosis [^111Piiq5]. Chest (2002). Low credibility.

Pulmonary fibrosis is a component of over 200 interstitial lung diseases. Some have known etiologies; however, for many diseases, the etiology remains unknown or obscure. This brief review examines the prevalence and classification of these diseases, the approach to be taken for the investigation of a patient suspected of having pulmonary fibrosis, the indications for the performance of lung biopsy, and thoughts concerning the pathogenesis of the idiopathic forms of fibrotic lung disease. A brief review of established and emerging therapeutic strategies is included.

---

### 2022 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension [^111QFQeT]. European Heart Journal (2022). High credibility.

Regarding medical management for idiopathic pulmonary fibrosis, specifically concerning the management of pulmonary hypertension, the ERS/ESC 2022 guidelines recommend referring patients with lung disease and suspected severe pulmonary hypertension, or in cases where there is uncertainty regarding the treatment of pulmonary hypertension, to a pulmonary hypertension center.

---

### Guidelines or guidance for better idiopathic pulmonary fibrosis management [^114AtRGF]. BMC Medicine (2016). Low credibility.

Evidence-based guidelines summarize the available research using a comprehensive literature approach and provide unbiased recommendations reflecting this research. However, this emphasis on methodology can lead to a lack of practicability and guidance in areas with insufficient evidence. The empirical approach, based on expert advice, can offer guidance, especially in areas with little or no formal evidence, but it may still be prone to biased recommendations. Thus, both approaches can potentially negatively impact patients. A synthesis of these potentially complementary approaches seems appropriate to provide optimal guidance in the treatment of all patients.

---

### Bronchoalveolar lavage in idiopathic pulmonary fibrosis: What does it tell us [^112gBJ4G]. Respiratory Medicine (2010). Low credibility.

Bronchoalveolar lavage (BAL) has only a limited role in the diagnosis of idiopathic pulmonary fibrosis (IPF). A finding of raised neutrophils (> 5%) and eosinophils (> 2%) is characteristic but not diagnostic of IPF. BAL cell count does not clearly differentiate between fibrotic non-specific interstitial pneumonia and IPF, either diagnostically or prognostically. BAL in IPF should be considered in all patients with suspected infection, malignancy, or acute exacerbations. In such cases, it may be diagnostic. Due to a shortage of research and conflicting results, BAL fluid analysis has very little clinical relevance in determining prognosis and response to treatment in IPF.

---

### Diagnosis of idiopathic pulmonary fibrosis. An official ATS/ERS/JRS/ALAT clinical practice guideline [^113U9XXW]. American Journal of Respiratory and Critical Care Medicine (2018). High credibility.

Regarding diagnostic investigations for idiopathic pulmonary fibrosis, particularly with respect to history and physical examination, the ALAT/ATS/ERS/JRS 2018 guidelines recommend eliciting a detailed history of medication use and environmental exposures at home, work, and other places the patient frequently visits to exclude potential causes of ILD.

---

### Focus on idiopathic pulmonary fibrosis: Advancing approaches to diagnosis, prognosis, and treatment [^1113RatU]. Chest (2018). Low credibility.

Idiopathic pulmonary fibrosis (IPF) is a specific form of chronic, progressive, fibrotic lung disease of unknown cause, associated with substantial health-care utilization and high rates of mortality. The clinical symptoms of IPF are nonspecific and overlap with many pulmonary and cardiac diseases, making differential diagnosis challenging. The American Thoracic Society/European Respiratory Society/Japanese Respiratory Society/Latin American Thoracic Association (ATS/ERS/JRS/ALAT) guidelines strongly recommend a multidisciplinary approach to the diagnosis of interstitial lung diseases; however, there are several limitations to the feasibility of this approach in clinical practice.

Although early diagnosis is relevant to any chronic, progressive, and irreversible disorder, it is crucially important that effective treatments for IPF are prescribed without delay. A window of opportunity may exist during which time treatment can have optimal outcomes. Evidence on the clinical management of IPF is rapidly evolving, and key updates were made to the most recent ATS/ERS/JRS/ALAT guidelines.

The widely used combination of prednisone, azathioprine, and N-acetylcysteine has now been associated with increased risk of hospitalization and death compared with placebo in patients with IPF. These treatments and others for IPF have been mostly supportive, but recently, pirfenidone and nintedanib have demonstrated efficacy in reducing functional decline and disease progression in IPF.

---

### Idiopathic pulmonary fibrosis (an update) and progressive pulmonary fibrosis in adults: An official ATS/ERS/JRS/ALAT clinical practice guideline [^112uHc3D]. American Journal of Respiratory and Critical Care Medicine (2022). Low credibility.

The histopathological features of UIP, as well as probable UIP, have been reviewed and confirmed. A diagnosis of UIP based on biopsy involves a combination of: 1) patchy dense fibrosis with architectural distortion (i.e. destructive scarring and/or honeycombing); 2) a preference for subpleural and paraseptal lung parenchyma; 3) fibroblast foci; and 4) the absence of features suggesting an alternative diagnosis. When these features are present, a UIP pattern can be confidently established. "Probable UIP" refers to cases where some findings are present without features suggesting an alternative diagnosis.

- **TBLC application**: The committee noted that the evolving use of TBLC merits discussion. Applying histopathological criteria for UIP is more challenging with TBLC specimens because: 1) the subpleural predominance of pathologic changes may not be readily apparent; and 2) potential sampling errors can make it harder to exclude features suggestive of alternative diagnoses. Compared with surgical lung biopsy (SLB), TBLC tends to show a probable UIP pattern rather than a definite UIP pattern, due to limited sampling of subpleural lung parenchyma. Despite this, patchy fibrosis, fibroblast foci, and absence of features suggesting an alternative diagnosis usually suffice to establish a probable UIP pattern using TBLC. Combining UIP and probable UIP patterns within the context of multidisciplinary discussion (MDD) can provide a more comprehensive diagnostic approach.

---

### Idiopathic pulmonary fibrosis - clinical management guided by the evidence-based GRADE approach: What arguments can be made against transparency in guideline development [^116cmc3S]. BMC Medicine (2016). Low credibility.

Evidence-based guidelines have undergone intense evolution over the last 15 years. The main driver behind this transformation has been the change in focus from what used to be called expert- or consensus-based to evidence-driven recommendations. This distinction represents a typical misunderstanding, as even in the era of evidence-based guidelines, recommendations are developed by clinical experts in the field and require consensus of panel members on the best possible treatment options. It is the transparent link between the evidence and the recommendations, and the requirement of making structured expert judgments, that represents a shift in the guideline development paradigm. This is true even for evidence-based guidelines that focus on complex and rare diseases such as idiopathic pulmonary fibrosis (IPF).

In 2000, a selected panel of international experts in the field of interstitial lung diseases provided a guideline for the diagnosis and management of IPF. Due to the paucity of evidence available and the relatively immature field of guideline methodology, this document was developed using the conventional consensus-approach based on the opinions of the few expert panel members without a systematic review of the literature or formal quality of evidence evaluation. Regardless, this document, then considered state of the art for the disease, provided useful direction to clinicians in diagnosing and managing patients with IPF. Over the next decade, an increasing number of studies in the field of IPF were published based on this guidance document.

---

### ESR essentials: imaging in fibrotic lung diseases-practice recommendations by the European Society of Thoracic Imaging [^114qtsha]. European Radiology (2025). Low credibility.

Chest CT with high-resolution technique is the recommended imaging modality to correctly recognize signs, patterns, and distribution of pulmonary fibrosis. A slice thickness of ≤ 1.5 mm and a high-resolution reconstruction algorithm are the basic requirements for a high-quality technique (Level of evidence: low). The accurate interpretation of CT pattern, along with clinical and laboratory data, often leads to a non-invasive diagnosis of specific fibrotic lung diseases (FLDs). Biopsy is recommended for cases with indeterminate radiologic-clinical features or in situations impacting therapeutic decision-making (Level of evidence: low).

FLDs may show progressive behavior and reduced survival, emphasizing the importance of early diagnosis of fibrosis and prompt identification of disease progression. This is crucial for initiating antifibrotic treatment for patients with idiopathic pulmonary fibrosis (IPF), as well as for non-IPF patients showing a progressive phenotype (Level of evidence: low). Careful comparison with previous CT examinations is essential to assess progression.

---

### Idiopathic pulmonary fibrosis in the United States: Time to diagnosis and treatment [^113hMema]. BMC Pulmonary Medicine (2023). Low credibility.

Despite increasing knowledge regarding the risk factors and available treatments for idiopathic pulmonary fibrosis (IPF), delays in the diagnosis of this disorder and the initiation of therapy persist. Furthermore, prognosis remains poor following diagnosis. In addition, anti-fibrotic therapy is underutilized in our cohort. We hope to reduce the delay to IPF diagnosis and treatment initiation by increasing the awareness of care for IPF patients and by enhancing education for providers on the appropriate diagnostic approach.

---

### An official ATS/ERS/JRS/ALAT statement: Idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management [^116fgYr6]. American Journal of Respiratory and Critical Care Medicine (2011). High credibility.

Regarding the screening and diagnosis of idiopathic pulmonary fibrosis, the 2011 ALAT/ATS/ERS/JRS guidelines recommend establishing the diagnosis of IPF based on the following:

- **Exclusion of other known causes of ILD**: This includes domestic and occupational environmental exposures, connective tissue disease, and drug toxicity.

- **Presence of a usual interstitial pneumonia pattern on HRCT**: Applicable to patients not subjected to surgical lung biopsy.

- **Specific combinations of HRCT and surgical lung biopsy patterns**: For patients subjected to surgical lung biopsy.

---

### Idiopathic pulmonary fibrosis: early detection and referral [^114HoiS8]. Respiratory Medicine (2014). Low credibility.

Idiopathic pulmonary fibrosis (IPF), a devastating progressive interstitial lung disease (ILD) with no known cause or cure, is the most common and deadly of the idiopathic interstitial pneumonias. With a median survival of 3–5 years following diagnosis, IPF is characterized by a progressive decline in lung function and quality of life in most patients. Vigilance among clinicians in recognizing IPF early in the disease course remains critical to properly caring for these patients, as this provides the widest range of management options.

When IPF is suspected, a multidisciplinary evaluation (MDE) by a clinician, radiologist, and pathologist with ILD expertise should occur, as this improves diagnostic agreement in both community and academic settings. When community MDE is not possible, or diagnostic doubt exists, referral to an ILD center should be considered. ILD center referral may also provide access to specialized care, including clinical trials and lung transplantation, and should be considered for any patient with an established diagnosis of IPF.

---

### Practical application and validation of the 2018 ATS/ERS/JRS/ALAT and Fleischner Society guidelines for the diagnosis of idiopathic pulmonary fibrosis [^113bETkA]. Respiratory Research (2021). Low credibility.

Accurate diagnosis of idiopathic pulmonary fibrosis (IPF) is essential to inform prognosis and treatment. In 2018, the ATS/ERS/JRS/ALAT and Fleischner Society released new diagnostic guidelines for usual interstitial pneumonitis (UIP)/IPF. These guidelines added probable UIP as a CT category based on prior studies demonstrating this category had relatively high positive predictive value (PPV) for histopathologic UIP/probable UIP. This study applies the 2018 ATS/ERS/JRS/ALAT and Fleischner Society guidelines to determine test characteristics of CT categories in academic clinical practice.

- **Methods**: CT and histopathology were evaluated by three thoracic radiologists and two thoracic pathologists. A comparison of consensus categorization by the 2018 ATS and Fleischner Society guidelines using CT and histopathology was performed.

- **Results**: Of patients with CT UIP, 87% (PPV, 95% CI: 60–98%) had histopathologic UIP with 97% (CI: 90–100%) specificity. Of patients with CT probable UIP, 38% (PPV, CI: 14–68%) had histopathologic UIP, and 46% (PPV, CI: 19–75%) had either histopathologic UIP or probable UIP, with 88% (CI: 77–95%) specificity. Patients with CT indeterminate and alternative diagnosis had histopathologic UIP in 27% (PPV, CI: 6–61%) and 21% (PPV, CI: 11–33%) of cases, with specificities of 90% (CI: 80–96%) and 25% (CI: 16–37%). Interobserver variability (kappa) between radiologists ranged from 0.32 to 0.81.

- **Conclusions**: CT UIP and probable UIP have high specificity for histopathologic UIP, and CT UIP has a high PPV for histopathologic UIP. The PPV of CT probable UIP was 46% for combined histopathologic assessments.

---

### "Any fool can make a rule and any fool will mind it" [^114j8Fmq]. BMC Medicine (2016). Low credibility.

In roughly half of idiopathic pulmonary fibrosis (IPF) patients, the ATS/ERS/JRS/ALAT 2011 diagnostic criteria for IPF are not satisfied, and the disease remains unclassifiable. Clinicians must speculate on the best course of action — whether to manage the disease according to a diagnosis of alternative disorders or to apply IPF-validated anti-fibrotic therapies. In a nutshell, the ATS/ERS/JRS/ALAT 2011 IPF diagnostic guidelines are 'broken'.
How has it come to this? The pace of recent events is partly to blame. In 2009/2010, when the ATS/ERS/JRS/ALAT guidelines were formulated, there was no universally accepted therapy known to delay disease progression, and it was generally agreed that the best management consisted of participation in a novel treatment trial. Rigorous diagnostic criteria are required in drug trials. More importantly, a treatment option, in the form of triple therapy with low-dose prednisolone, azathioprine, and N-acetyl cysteine, was available. This option could, until recently, reasonably be applied equally in IPF or in the realistic differential diagnoses in which immune dysregulation is thought to play a primary pathogenetic role. Thus, the ATS/ERS/JRS/ALAT 2011 guidelines provided appropriate diagnostic rigour for trial purposes, and at that time, it could be argued that patients disenfranchised by IPF diagnostic criteria were not disadvantaged for practical management purposes. Perhaps it was not possible in 2011 to do better than this. However, everything changed irrevocably when IPF-specific therapies were validated.

---

### Clinical characteristics of patients with familial idiopathic pulmonary fibrosis (f-IPF) [^112483D6]. BMC Pulmonary Medicine (2019). Low credibility.

- **Distribution of the diagnoses in f-IPF vs. s-IIP cohort**: Of the 28 identified index patients, all had the diagnosis of IPF with the following levels of diagnostic confidence: 24 definite, three probable, and one possible. Together with 51 affected family members (a total of 79 patients), these individuals were diagnosed with IPF (56%), nonspecific interstitial pneumonia (NSIP, 3%), unclassifiable idiopathic interstitial pneumonia (u-IIP, 1%), and other diffuse parenchymal lung diseases (DPLD, 40%).

	- The IPF diagnoses were conducted in accordance with the Official ATS/ERS/JRS/ALAT Clinical Practice Guideline 2011. In cases where clinical, radiological, and pathological information was collected and conformed to the official guideline criteria, an IPF diagnosis could be confirmed. However, not all clinical data for the relatives of index patients were available. In some instances, especially if the relative had died, further reliable information could not be retrieved. In such cases, a diagnosis of DPLD was considered without further differentiation.

	- Evidence level A for f-IPF was met by 14 families, while the remaining 14 families corresponded to evidence level B. In comparison, the s-IIP group (286 patients) showed the following distribution of diagnoses: IPF (51.2%), NSIP (5.9%), u-IIP (24%), cryptogenic organizing pneumonia (COP, 14.6%), and other DPLD (4%).

---

### Idiopathic pulmonary fibrosis (an update) and progressive pulmonary fibrosis in adults: An official ATS/ERS/JRS/ALAT clinical practice guideline [^116M2aHh]. American Journal of Respiratory and Critical Care Medicine (2022). High credibility.

The committee asked, "Should genomic classifier testing be performed for the purpose of diagnosing UIP in patients with ILD of undetermined type who are undergoing transbronchial forceps biopsy?" The systematic review that informed the committee's recommendation is published independently; we summarize the salient findings. Diagnostic test characteristics were rated as critical outcomes, while diagnostic agreement, diagnostic confidence, and the adverse consequences of misclassification were rated as important outcomes.

The systematic review identified four relevant studies, which included a total of 195 patients with ILD of unknown type. All of the studies were accuracy studies. Two of the studies also measured agreement in the categorization of UIP and non-UIP when a genomic classifier was or was not used, as well as diagnostic confidence before and after the use of a genomic classifier.

All four studies reported diagnostic test characteristics of genomic classifier testing and were included in a meta-analysis. The individual studies reported sensitivity ranging from 59% to 80% and specificity ranging from 78% to 100% using histopathological diagnosis from samples obtained by SLB, TBLC, or MDD as the reference standard. When aggregated by meta-analysis, genomic classifier testing identified the UIP pattern with sensitivity and specificity of 68% and 92%, respectively, in patients with ILD of unknown type.

Two studies reported diagnostic agreement and confidence. Multidisciplinary teams evaluated anonymized clinical information, radiographic findings, and histopathological data both before and after the genomic classifier results were available.

---

### Idiopathic pulmonary fibrosis — a systematic review on methodology for the collection of epidemiological data [^1141YZCU]. BMC Pulmonary Medicine (2013). Low credibility.

Diagnostics and treatment of idiopathic pulmonary fibrosis (IPF) are currently undergoing changes. In the most recent guidelines, the diagnostic criteria for IPF are defined more accurately than they have been previously. Simultaneously, IPF treatment is experiencing the most significant shift in its history; the first drug intended for the prevention of IPF progression, pirfenidone, is entering clinical use in Europe, Canada, and Asia. Additionally, an interim publication of the PANTHER trial revealed that the commonly used triple-drug treatment, namely prednisolone, azathioprine, and N-acetylcysteine, may be harmful to IPF patients. Compared to those who received a placebo, individuals receiving triple-drug therapy had increased mortality.

Epidemiological data on IPF are sparse, and changes in the classification of idiopathic interstitial pneumonias (IIP) and diagnostics make the comparison of data from various decades difficult. Until the 1990s, idiopathic pulmonary fibrosis encompassed a heterogeneous group of different interstitial diseases. The ATS/ERS consensus statement on diagnosis and treatment in 2000 and the classification of IIPs in 2002 defined IPF more accurately than it had been previously. In the new guideline, radiological and histological criteria of UIP (usual interstitial pneumonia) are defined more precisely than before: if high-resolution computed tomography (HRCT) features reveal a typical UIP pattern, IPF can be diagnosed without histological analysis. In contrast, if HRCT features show either possible UIP or no UIP features, a surgical lung biopsy should be performed.

---

### Diagnostic criteria for idiopathic pulmonary fibrosis: A Fleischner Society White Paper [^111cvzSR]. The Lancet Respiratory Medicine (2018). High credibility.

This review provides an updated approach to the diagnosis of idiopathic pulmonary fibrosis (IPF), based on a systematic search of the medical literature and the expert opinion of members of the Fleischner Society. A checklist is provided for the clinical evaluation of patients with suspected usual interstitial pneumonia (UIP).

The role of CT is expanded to permit diagnosis of IPF without surgical lung biopsy in select cases when CT shows a probable UIP pattern. Additional investigations, including surgical lung biopsy, should be considered in patients with either clinical or CT findings that are indeterminate for IPF. A multidisciplinary approach is particularly important when deciding to perform additional diagnostic assessments, integrating biopsy results with clinical and CT features, and establishing a working diagnosis of IPF if lung tissue is not available. A working diagnosis of IPF should be reviewed at regular intervals since the diagnosis might change. Criteria are presented to establish confident and working diagnoses of IPF.

---

### Diagnosis of idiopathic pulmonary fibrosis: An official ATS/ERS/JRS/ALAT clinical practice guideline [^1144VC7o]. American Journal of Respiratory and Critical Care Medicine (2018). High credibility.

Regarding diagnostic investigations for idiopathic pulmonary fibrosis, more specifically with respect to CT, the ALAT/ATS/ERS/JRS 2018 guidelines recommend obtaining a high-resolution CT (HRCT) of the chest for the evaluation of patients with IPF.

---

### Diagnosis of idiopathic pulmonary fibrosis. An official ATS/ERS/JRS/ALAT clinical practice guideline [^112PERpW]. American Journal of Respiratory and Critical Care Medicine (2018). Low credibility.

This document provides clinical recommendations for the diagnosis of idiopathic pulmonary fibrosis (IPF). It represents a collaborative effort between the American Thoracic Society, European Respiratory Society, Japanese Respiratory Society, and Latin American Thoracic Society.

- **Methods**: The evidence syntheses were discussed and recommendations formulated by a multidisciplinary committee of IPF experts. The evidence was appraised and recommendations were formulated, written, and graded using the Grading of Recommendations, Assessment, Development, and Evaluation approach.

- **Results**: The guideline panel updated the diagnostic criteria for IPF. Previously defined patterns of usual interstitial pneumonia (UIP) were refined to patterns of UIP, probable UIP, indeterminate, and alternate diagnosis. For patients with newly detected interstitial lung disease (ILD) who have a high-resolution computed tomography scan pattern of probable UIP, indeterminate, or an alternative diagnosis, conditional recommendations were made for performing BAL and surgical lung biopsy; because of lack of evidence, no recommendation was made for, or against performing transbronchial lung biopsy or lung cryobiopsy.

In contrast, for patients with newly detected ILD who have a high-resolution computed tomography scan pattern of UIP, strong recommendations were made against performing surgical lung biopsy, transbronchial lung biopsy, and lung cryobiopsy, and a conditional recommendation was made against performing BAL. Additional recommendations included a conditional recommendation for multidisciplinary evaluation.

---

### Assessment of current practice in the diagnosis and therapy of idiopathic pulmonary fibrosis [^113hR8AU]. Respiratory Medicine (2008). Low credibility.

The consensus statement on the diagnosis and therapy of idiopathic pulmonary fibrosis (IPF) formulated by the American Thoracic Society/European Respiratory Society (ATS/ERS) was published in 2000. Acceptance and implementation of these guidelines have not been assessed. We surveyed the fellows of the American College of Chest Physicians (FCCP) to establish practice patterns regarding the diagnosis and therapy of IPF.

- **Methods**: We electronically distributed a 32-item questionnaire to all 6,443 pulmonary medicine board-certified fellows of the American College of Chest Physicians. The response rate was 13%. Demographic characteristics were similar between respondents and non-respondents.

- **Results**: Seventy-two percent of respondents were familiar with the ATS/ERS consensus statement and 63% found it clinically useful. However, a similar number of respondents indicated that an update is needed. Bronchoscopy and surgical lung biopsy are used infrequently. Forty-five percent of pulmonary physicians advocate providing only supportive care for patients outside of clinical trials. If pharmacological therapy is recommended, prednisone (either alone or in combination with azathioprine) or off-label agents are preferentially prescribed. Despite physician awareness (79%) of clinical trials, interested patients are not consistently referred. A majority of respondents (61%) felt that lung transplantation represents the only effective therapy for IPF, and 86% refer their patients to lung transplant centers.

- **Conclusions**: There is substantial variability among pulmonary physicians in terms of the diagnosis and management of IPF.

---

### Idiopathic pulmonary fibrosis (an update) and progressive pulmonary fibrosis in adults: An official ATS/ERS/JRS/ALAT clinical practice guideline [^113XEDap]. American Journal of Respiratory and Critical Care Medicine (2022). High credibility.

An international, multidisciplinary committee of experts described the radiological and histopathological features of UIP, diagnostic testing for IPF, and treatment of GER in IPF. The committee also defined PPF, described the physiological, radiological, and histopathological features of PPF, and addressed the antifibrotic treatment of PPF.

Two specific questions pertaining to the diagnosis of IPF, two specific questions pertaining to the treatment of IPF, and two specific questions pertaining to pharmacotherapy for PPF were answered with evidence-based, graded recommendations. These recommendations are not mandates, as they cannot account for all unique clinical circumstances, and they should be revisited as new evidence is published. This guideline was reviewed by the ATS Quality Improvement and Implementation Committee; it was determined that none of the recommendations are appropriate targets for performance measures.

---

### Patient characteristics and survival for progressive pulmonary fibrosis using different definitions [^116Xyr1Y]. American Journal of Respiratory and Critical Care Medicine (2023). High credibility.

Patients with fibrotic interstitial lung disease (ILD) exhibit heterogeneous disease courses, with idiopathic pulmonary fibrosis (IPF) being the prototypic subtype with a mean survival of four years. A large proportion of patients with non-IPF fibrotic ILD have similar courses and nearly identical therapeutic responses to antifibrotic therapy compared with patients with IPF. These patients are now labeled as having progressive pulmonary fibrosis (PPF); however, its optimal definition remains uncertain. Different thresholds and combinations of symptom, physiological, and radiological criteria with varying observation durations have been used to define PPF in clinical trials and a recent clinical practice guideline.

In this multicenter cohort study, we examined the characteristics of patients with PPF according to recent guidelines and clinical trials and compared their survival with that of patients with IPF, hypothesizing that patient characteristics and survival would vary across definitions of PPF. Some of the results of this study have been previously reported in the form of an abstract.

---

### 2022 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension [^111hs38H]. European Heart Journal (2022). High credibility.

Regarding diagnostic investigations for idiopathic pulmonary fibrosis, and more specifically with respect to evaluation for pulmonary hypertension, the ERS/ESC 2022 guidelines recommend obtaining echocardiography when pulmonary hypertension is suspected in patients with lung disease. The results should be interpreted in conjunction with arterial blood gas analysis, pulmonary function tests (including lung diffusion capacity for CO), and CT.

---

### Idiopathic pulmonary fibrosis (an update) and progressive pulmonary fibrosis in adults: An official ATS/ERS/JRS/ALAT clinical practice guideline [^111yQ7Hm]. American Journal of Respiratory and Critical Care Medicine (2022). High credibility.

Idiopathic pulmonary fibrosis (IPF) diagnosis is based on high-resolution computed tomography (HRCT) and biopsy patterns developed through consensus discussion. A patient is considered "clinically suspected of having IPF" when they exhibit unexplained patterns of bilateral pulmonary fibrosis on chest radiography or chest computed tomography, bibasilar inspiratory crackles, and age over 60 years. Further diagnostic indications include:

- **Middle-aged adults**: For those over 40 and 50 years old, or in women over 60 years old, extensive (> 30%) reticulation on HRCT and age over 70 years are key indicators.
- **BAL fluid analysis**: An increase in neutrophils and/or lack of lymphocytosis.
- **Multidisciplinary discussion**: A confident diagnosis of IPF can be reached after such evaluation.

For cases indeterminate for IPF without an adequate biopsy, diagnosis remains inconclusive. However, with an adequate biopsy, cases may be reclassified to a more specific diagnosis following multidisciplinary discussion or additional consultations.

---

### Significance of bronchoalveolar lavage for the diagnosis of idiopathic pulmonary fibrosis [^112Udran]. American Journal of Respiratory and Critical Care Medicine (2009). Low credibility.

According to the 2002 ATS/ERS Consensus Classification, a confident diagnosis of idiopathic pulmonary fibrosis (IPF) without surgical lung biopsy is made with consistent clinical and physiological findings and the typical features on high-resolution computed tomography (HRCT). Bronchoalveolar lavage (BAL) and/or transbronchial biopsy, one of four major criteria in the 2000 ATS/ERS IPF Statement, was no longer essential in the diagnostic algorithm of the 2002 ATS/ERS Consensus Classification.

- **Objectives**: To evaluate the additional utility of BAL for the diagnosis of IPF.

- **Methods**: A total of 101 patients with suspected IPF on HRCT were studied. Twenty-seven patients were excluded because of a lack of functional impairment (n = 20), an underlying condition causing fibrosis (n = 5), or a clinical history inconsistent with IPF (n = 2). The remaining 74 patients met all the criteria recommended in the 2002 ATS/ERS Consensus Classification for making a diagnosis in the absence of surgical biopsy. The final diagnosis was made with further examinations, including pathological analysis, in patients who showed inconsistent findings for IPF on BAL.

- **Measurements and main results**: A cut-off level of 30% for lymphocytes in BAL demonstrated a favorable discriminative power for the diagnosis of IPF. Six of the 74 patients (8%) showed a lymphocytosis of 30% or greater in BAL. Their final diagnoses were idiopathic nonspecific interstitial pneumonia (n = 3) and extrinsic allergic alveolitis (n = 3). The change in perception of the diagnosis was validated by a surgical biopsy in two cases.

---

### The diagnosis of idiopathic pulmonary fibrosis: current and future approaches [^112wy7iA]. The Lancet Respiratory Medicine (2017). Low credibility.

With the recent development of two effective treatments for patients with idiopathic pulmonary fibrosis, an accurate diagnosis is crucial. The traditional approach to diagnosis emphasizes the importance of thorough clinical and laboratory evaluations to exclude secondary causes of disease. High-resolution CT is a critical initial diagnostic test and acts as a tool to identify patients who should undergo a surgical lung biopsy to secure a definitive histological diagnosis of a usual interstitial pneumonia pattern.

This diagnostic approach faces several challenges. Many patients with suspected idiopathic pulmonary fibrosis present with atypical high-resolution CT characteristics but are unfit for surgical lung biopsy, preventing a confident diagnosis. The state of the art suggests an iterative, multidisciplinary process that incorporates available clinical, laboratory, imaging, and histological features. Recent research has explored genomic techniques to molecularly phenotype patients with interstitial lung disease.

In the future, clinicians will probably use blood-specific or lung-specific molecular markers in combination with other clinical, physiological, and imaging features to enhance diagnostic efforts, refine prognostic recommendations, and influence the initial or subsequent treatment options. There is an urgent and increasing need for well-designed, large, prospective studies measuring the effect of different diagnostic approaches. Ultimately, this will help to inform the development of guidelines and tailor clinical practice for the benefit of patients.

---

### 2022 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension [^115rLgmb]. European Heart Journal (2022). High credibility.

Regarding the medical management of idiopathic pulmonary fibrosis, particularly in the context of managing pulmonary hypertension, the ERS/ESC 2022 guidelines recommend optimizing the treatment of IPF. This includes addressing hypoxemia, sleep-disordered breathing, and/or alveolar hypoventilation in patients with suspected pulmonary hypertension where indicated.

---

### Idiopathic pulmonary fibrosis (an update) and progressive pulmonary fibrosis in adults: An official ATS/ERS/JRS/ALAT clinical practice guideline [^114Fu67p]. American Journal of Respiratory and Critical Care Medicine (2022). Low credibility.

The guideline committee conclusions highlight the nature of the evidence as observational and indirect. The original question focused on patients with idiopathic pulmonary fibrosis (IPF) who had confirmed gastroesophageal reflux (GER); however, the evidence considered involved unselected IPF patients, both with and without confirmed GER. The committee deliberated whether to issue guidance specifically for patients with confirmed GER or for all IPF patients, and they voted by a two-thirds majority to provide guidance for all IPF patients, irrespective of GER confirmation. In the absence of definitive benefits, the committee decided to make a conditional recommendation against using antacid medication in patients with IPF solely to improve respiratory outcomes.

The committee emphasized three key points. First, while antacid therapy might be beneficial for patients with confirmed GER, this benefit could be obscured by the inclusion of IPF patients without GER in studies. Thus, guidance may change if efficacy is evaluated in patients stratified by GER status. Second, the quality of evidence was very low, leading to very low confidence in estimated effects, and these should be interpreted with caution. Lastly, antacid medication might still be appropriate for IPF patients showing symptoms of GERD to improve GER-related outcomes.

---

### Progressive fibrosing interstitial lung disease: Clinical uncertainties, consensus recommendations, and research priorities [^115kM7dR]. The Lancet Respiratory Medicine (2020). Low credibility.

Within the spectrum of fibrosing interstitial lung diseases (ILDs), there exists a subset of patients who experience inexorable progression of pulmonary fibrosis despite treatment, known as the progressive fibrotic phenotype. Although the concept of progressive fibrosing ILD has been applied largely to patients with idiopathic pulmonary fibrosis (IPF), there is now an increasing focus on irreversible progressive fibrosis in a proportion of patients with various underlying ILD diagnoses. Evidence has emerged to support a possible role for antifibrotic therapy in these patients.

In this position paper, we discuss the importance of retaining diagnostic scrutiny within the multidisciplinary team and suggest a multidomain definition for progressive fibrosis. We consider the potential role of antifibrotic drugs as second-line therapy in the treatment algorithm for patients with progressive non-IPF ILD. We highlight risk factors that might predispose individuals to developing progressive fibrosis and discuss key uncertainties alongside future directions for research and clinical practice.

---

### Acute exacerbation of idiopathic pulmonary fibrosis. An international working group report [^116z56bm]. American Journal of Respiratory and Critical Care Medicine (2016). Low credibility.

Acute exacerbation of idiopathic pulmonary fibrosis has been defined as an acute, clinically significant respiratory deterioration of unidentifiable cause. The objective of this international working group report on acute exacerbation of idiopathic pulmonary fibrosis was to provide a comprehensive update on the topic. A literature review was conducted to identify all relevant English text publications and abstracts. Evidence-based updates on the epidemiology, etiology, risk factors, prognosis, and management of acute exacerbations of idiopathic pulmonary fibrosis are provided. To better reflect the state of knowledge and improve the feasibility of future research into its etiology and treatment, the working group proposes a new conceptual framework for acute respiratory deterioration in idiopathic pulmonary fibrosis and a revised definition and diagnostic criteria for acute exacerbation of idiopathic pulmonary fibrosis.

---

### ESR essentials: imaging in fibrotic lung diseases-practice recommendations by the European Society of Thoracic Imaging [^114fGbpw]. European Radiology (2025). Low credibility.

A CT scan using high-resolution technique is the recommended imaging modality to correctly recognize signs, patterns, and distribution of pulmonary fibrosis. Systematic interpretation of CT patterns according to international guidelines leads to a non-invasive, accurate diagnosis of fibrotic lung diseases (FLDs) or helps to narrow down the differential diagnosis in the context of interdisciplinary discussion. A biopsy is recommended in indeterminate and discordant cases.

FLDs may show progressive behavior and reduced survival. Individuals with interstitial lung abnormalities (ILAs) might also be at increased risk of disease progression. The major task is to detect these subjects and direct them to the correct management. An early diagnosis of fibrosis and prompt identification of disease progression are crucial to grant antifibrotic treatment to patients showing a progressive phenotype. FLD patients may also develop complications, such as acute exacerbations (AEs), which are commonly associated with a worsening prognosis.

In this field, the radiologist plays a pivotal role. Careful comparison with previous CT examinations is essential to assess progression and complications. The use of reconstructions to provide information on fibrosis distribution, change in pattern, and increased extent of lung fibrosis should be recommended. Final diagnosis and therapeutic decisions should be made in collaboration with pulmonologists, rheumatologists, and pathologists to improve FLD patient management.

---

### Idiopathic pulmonary fibrosis - clinical management guided by the evidence-based GRADE approach: what arguments can be made against transparency in guideline development [^11499ph9]. BMC Medicine (2016). Low credibility.

Some believe that the opinion of experts in the field is driven by their understanding of the clinical problem and their accurate interpretation of the underlying literature, and therefore such recommendations may be considered, in effect, evidence-based. This approach has gone wrong on many occasions. Using a transparent and structured process in guideline development not only mandates a linkage of evidence to recommendation development but also ensures this linkage is explicit and systematically demonstrated.

In effect, this helps to limit the potential for bias. Guideline panel members may have strong opinions or academic bias surrounding a specific area in which they have clinical expertise, or they may have other biases related to interactions with academic colleagues or industry partners. In an attempt to address this, GRADE requires systematic or pragmatic searches of the literature and the production of evidence summaries such as evidence profiles, ideally based on pooled treatment effects and produced by panel members without conflict of interest (COI) or independent methodologists. The latter helps to ensure a fair and reproducible assessment of the literature addressing a specific clinical question.

---

### Idiopathic pulmonary fibrosis (an update) and progressive pulmonary fibrosis in adults: An official ATS/ERS/JRS/ALAT clinical practice guideline [^114fgch3]. American Journal of Respiratory and Critical Care Medicine (2022). High credibility.

There were several reasons that merging the UIP and probable UIP categories was considered: 1) there is increasing evidence that patients with the probable UIP pattern and UIP pattern on HRCT have similar disease behavior and clinical courses; 2) the likelihood of histologic confirmation of UIP in patients with the probable UIP pattern ranges from 80% to 85%; and 3) in the appropriate clinical context, histopathological confirmation of the UIP pattern is not required to ascertain the diagnosis of IPF in patients with either the probable UIP pattern or the UIP pattern.

Despite these reasons, the guideline committee opted to maintain the differentiation between the two patterns for several reasons: 1) studies describing the correlation of probable UIP with histopathological UIP are from expert settings, and correlation in alternative settings is unknown; 2) there is evidence suggesting that patients with probable UIP might have better survival; 3) the predictive value of the probable UIP CT pattern for histologic UIP is slightly lower than for the UIP CT pattern, suggesting that the probable UIP CT pattern may show more overlap with other fibrotic lung diseases such as fibrotic HP; and 4) there is evidence that the predictive value of a probable UIP pattern for histologic UIP is lower in individuals with relatively mild fibrosis and in younger individuals. Although the UIP pattern and probable UIP pattern remain separate, the diagnostic approaches for these entities are currently evolving.

---

### Update on pulmonary fibrosis: Not all fibrosis is created equally [^114SnhKW]. Archives of Pathology & Laboratory Medicine (2016). Low credibility.

Three distinct patterns of pulmonary fibrosis, including usual interstitial pneumonia, fibrotic nonspecific interstitial pneumonia, and airway-centered fibrosis, can be identified on surgical lung biopsies.

- **Objectives**: To compare the pathologic definitions, clinical and radiographic presentations, etiologies and differential diagnoses, treatments, and prognoses of usual interstitial pneumonia, fibrotic nonspecific interstitial pneumonia, and airway-centered fibrosis patterns, and to address the challenges and controversies related to pulmonary fibrosis.

- **Data sources**: Data were derived from published literature and clinical experience.

- **Conclusions**: Although there may be overlap, identification of the dominant form of fibrosis in a particular case can provide a general category of disease and assist in identifying an etiology.

---

### Diagnostic likelihood thresholds that define a working diagnosis of idiopathic pulmonary fibrosis [^111jWdgZ]. American Journal of Respiratory and Critical Care Medicine (2019). Low credibility.

The level of diagnostic likelihood at which physicians prescribe antifibrotic therapy without requesting surgical lung biopsy (SLB) in patients suspected of idiopathic pulmonary fibrosis (IPF) is unknown. The study aims to determine how often physicians advocate SLB in patient subgroups defined by IPF likelihood and the risk associated with SLB, as well as to identify the level of diagnostic likelihood at which physicians prescribe antifibrotic therapy without requesting SLB.

An international cohort of respiratory physicians evaluated 60 cases of interstitial lung disease, providing: 1) differential diagnoses with diagnostic likelihood; 2) a decision on the need for SLB; and 3) initial management. Diagnoses were stratified according to diagnostic likelihood bands described by Ryerson and colleagues.

A total of 404 physicians evaluated the 60 cases, resulting in 24,240 physician-patient evaluations. IPF was part of the differential diagnosis in 9,958 out of 24,240 (41.1%) evaluations. SLB was requested in 8.1%, 29.6%, and 48.4% for definite, provisional high-confidence and provisional low-confidence diagnoses of IPF, respectively. Antifibrotic therapy was prescribed without requesting SLB in 63.0% of provisional high-confidence IPF diagnoses.

There was no significant mortality difference between cases given a definite diagnosis of IPF (90–100% diagnostic likelihood) and those given a provisional high-confidence IPF diagnosis (hazard ratio, 0.97; P = 0.65; 95% confidence interval, 0.90–1.04).

---

### Integrating clinical probability into the diagnostic approach to idiopathic pulmonary fibrosis: An international working group perspective [^113zkrzW]. American Journal of Respiratory and Critical Care Medicine (2022). Low credibility.

When considering the diagnosis of idiopathic pulmonary fibrosis (IPF), experienced clinicians integrate clinical features that help to differentiate IPF from other fibrosing interstitial lung diseases, thus generating a "pre-test" probability of IPF. The aim of this international working group perspective was to summarize these features using a tabulated approach similar to chest HRCT and histopathologic patterns reported in the international guidelines for the diagnosis of IPF, and to help formally incorporate these clinical likelihoods into diagnostic reasoning to facilitate the diagnosis of IPF.

- **Methods**: The committee group identified factors that influence the clinical likelihood of a diagnosis of IPF, which was categorized as a pre-test clinical probability of IPF into "high" (70–100%), "intermediate" (30–70%), or "low" (0–30%). After integration of radiological and histopathological features, the post-test probability of diagnosis was categorized into "definite" (90–100%), "high confidence" (70–89%), "low confidence" (51–69%), or "low" (0–50%) probability of IPF.

- **Findings**: A conceptual Bayesian framework was created, integrating the clinical likelihood of IPF ("pre-test probability of IPF") with the HRCT pattern, the histopathology pattern when available, and/or the pattern of observed disease behavior, into a "post-test probability of IPF".

- **Interpretation**: The diagnostic probability of IPF was expressed using an adapted diagnostic ontology for fibrotic interstitial lung diseases. This present approach will help incorporate clinical judgment into the diagnostic process.

---

### Idiopathic pulmonary fibrosis (an update) and progressive pulmonary fibrosis in adults: An official ATS/ERS/JRS/ALAT clinical practice guideline [^112MQjPa]. American Journal of Respiratory and Critical Care Medicine (2022). High credibility.

Idiopathic pulmonary fibrosis (IPF) is a chronic, fibrosing interstitial pneumonia of unknown cause that is associated with radiological and histologic features of usual interstitial pneumonia (UIP). It occurs primarily in older adults, is characterized by progressive worsening of dyspnea and lung function, and has a poor prognosis. Diagnosis and management of IPF were addressed in prior guidelines. A formal American Thoracic Society (ATS) and European Respiratory Society (ERS) proposal process determined that several topics from the previous guidelines warrant reassessment, including the following:

- **Radiological and histopathological features of UIP**: Diagnostic criteria, diagnostic and treatment approaches, and prior evidence-based recommendations about antacid medications and transbronchial lung cryobiopsy (TBLC).
- **New questions**: It was decided that new questions about antireflux surgery and genomic classifier testing should be addressed.

The acceptance of antifibrotic therapies for IPF led to the investigation of such therapies in other fibrotic lung diseases. While the IPF guidelines were being updated, a clinical trial reporting a beneficial effect of antifibrotic medication in interstitial lung diseases (ILDs) other than IPF that manifest progressive pulmonary fibrosis (PPF) was published, prompting a paradigm shift toward an en bloc approach to antifibrotic therapy. Given the importance and timeliness of the issue, the guideline committee was approved to expand its scope to also define progression of pulmonary fibrosis and to decide whether the en bloc approach should be employed.

---

### An official ATS/ERS/JRS/ALAT clinical practice guideline: Treatment of idiopathic pulmonary fibrosis. An update of the 2011 clinical practice guideline [^112wsGeZ]. American Journal of Respiratory and Critical Care Medicine (2015). Low credibility.

This document updates the American Thoracic Society/European Respiratory Society/Japanese Respiratory Society/Latin American Thoracic Association guideline on idiopathic pulmonary fibrosis treatment.

- **Methods**: Systematic reviews and, when appropriate, meta-analyses were performed to summarize all available evidence pertinent to our questions. The evidence was assessed using the GRADE (Grading of Recommendations, Assessment, Development and Evaluation) approach and then discussed by a multidisciplinary panel. Predetermined conflict-of-interest management strategies were applied, and recommendations were formulated, written, and graded exclusively by the nonconflicted panelists.

- **Results**: After considering the confidence in effect estimates, the importance of outcomes studied, desirable and undesirable consequences of treatment, cost, feasibility, acceptability of the intervention, and implications to health equity, recommendations were made for, or against specific treatment interventions.

- **Conclusions**: The panel formulated and provided the rationale for recommendations in favor of or against treatment interventions for idiopathic pulmonary fibrosis.

---

### Diagnosis of idiopathic pulmonary fibrosis. An official ATS/ERS/JRS/ALAT clinical practice guideline [^116UsWhr]. American Journal of Respiratory and Critical Care Medicine (2018). High credibility.

Regarding diagnostic procedures for idiopathic pulmonary fibrosis, more specifically with respect to bronchoalveolar lavage (BAL) fluid analysis, the ALAT/ATS/ERS/JRS 2018 guidelines recommend avoiding cellular analysis of BAL fluid in patients with definite usual interstitial pneumonia on high-resolution computed tomography (HRCT).

---

### Association of early suspected acute exacerbations of idiopathic pulmonary fibrosis with subsequent clinical outcomes and healthcare resource utilization [^114a37g4]. Respiratory Medicine (2015). Low credibility.

Idiopathic pulmonary fibrosis (IPF) may be complicated by episodes of acute exacerbation. This study quantified the association between the occurrence of suspected acute exacerbations of IPF (AEx-IPF) in the six months post-IPF diagnosis with clinical outcomes and IPF-related healthcare resource utilization (HRU).

- **Methods**: U.S. pulmonologists participated in a retrospective chart review of IPF patients. Patient eligibility criteria included: 1) ≥ 40 years of age and a confirmed date of first IPF diagnosis with HRCT and/or lung biopsy between January 2011 and June 2013; 2) two separate FVC results recorded around the time of the first diagnosis and six months post-diagnosis. Patients with a suspected AEx-IPF within six months post-diagnosis were categorized as "early AEx-IPF". Subsequent clinical outcomes and IPF-related HRU were assessed from six months post-diagnosis until the latest physician contact date.

- **Results**: The sample included 490 IPF patients from 168 pulmonologists; 72 (15%) patients had a suspected early AEx-IPF. At IPF diagnosis, the mean (SD) age was 61 (11) years, 68% were male, and the mean FVC percent predicted was 60% (26%). Compared to patients without a suspected early AEx-IPF, patients with an early AEx-IPF had a higher mortality risk (HR = 2.87, p < 0.001) and higher rates of subsequent suspected AEx-IPF (IRR = 3.87, p < 0.001), outpatient visits (IRR = 1.46, p < 0.001), ER visits (IRR = 4.39, p < 0.001), hospitalizations (IRR = 7.96, p < 0.001), and ICU stays (IRR = 9.74, p < 0.001).

- **Conclusions**: Using a large sample of IPF patients from varied practice settings, we found…

---

### Guidelines or guidance for better idiopathic pulmonary fibrosis management [^117Dy9pi]. BMC Medicine (2016). Low credibility.

The art of clinical decision making

As indicated by Rochwerg et al, evidence-based guidelines provide a comprehensive summary of the available evidence and a transparent process leading to recommendations that are not biased by personal experiences or opinions of individual experts. The strength of the GRADE methodology used in this process lies in the systematic and pragmatic literature search, which leads to an unbiased overview of the available evidence on a given topic. Its shortcoming is the exclusion of clinical experience and common sense not supported by formal evidence from well-designed clinical trials, as succinctly discussed by Wells.

This approach eventually leads to recommendations that lack practicability, exemplified in the diagnostic algorithm of the IPF guideline, which foresees surgical lung biopsy for patients with a non-informational HRCT. However, this procedure cannot be performed in many patients due to disease severity, comorbidities, or cost. Consequently, according to this guideline, a substantial number of patients are left without a diagnosis or treatment.

This differentiation has gained significance since the recent approval of nintedanib and pirfenidone, as the issue of whether these drugs should also be used in probable and possible IPF remains unresolved. While possible IPF patients have been included in the INPULSIS trials with nintedanib, only definite IPF patients were allowed in the ASCEND trial with pirfenidone. However, neither of these studies has led to a definite solution.

---

### Diagnosis of idiopathic pulmonary fibrosis. An official ATS/ERS/JRS/ALAT clinical practice guideline [^113f7aMQ]. American Journal of Respiratory and Critical Care Medicine (2018). High credibility.

Regarding diagnostic procedures for idiopathic pulmonary fibrosis, specifically with respect to bronchoalveolar lavage (BAL) fluid analysis, the 2018 ALAT/ATS/ERS/JRS guidelines recommend considering the performance of cellular analysis of BAL fluid. This is particularly advised for patients with probable usual interstitial pneumonia, indeterminate usual interstitial pneumonia, or an alternative diagnosis on high-resolution computed tomography (HRCT).

---

### Diagnosis of idiopathic pulmonary fibrosis. An official ATS/ERS/JRS/ALAT clinical practice guideline [^1178bTX6]. American Journal of Respiratory and Critical Care Medicine (2018). High credibility.

Regarding diagnostic investigations for idiopathic pulmonary fibrosis, specifically with respect to laboratory testing, the ALAT/ATS/ERS/JRS 2018 guidelines recommend obtaining serological testing to exclude connective tissue disease as a potential cause of the ILD.

---

### An official ATS/ERS/JRS/ALAT statement: Idiopathic pulmonary fibrosis: Evidence-based guidelines for diagnosis and management [^113abwYg]. American Journal of Respiratory and Critical Care Medicine (2011). High credibility.

Regarding the screening and diagnosis of idiopathic pulmonary fibrosis, specifically in relation to diagnosis, the ALAT/ATS/ERS/JRS 2011 guidelines recommend ensuring a multidisciplinary discussion. This discussion should include pulmonologists, radiologists, and pathologists experienced in diagnosing interstitial lung disease (ILD) to increase the accuracy of the diagnosis of idiopathic pulmonary fibrosis (IPF).

---

### Histopathologic assessment of suspected idiopathic pulmonary fibrosis: Where we are and where we need to go [^115UTCMT]. Archives of Pathology & Laboratory Medicine (2020). Low credibility.

Accurate diagnosis of idiopathic pulmonary fibrosis (IPF) requires a multidisciplinary approach, including clinical, radiologic, and often pathologic assessments. In 2018, the American Thoracic Society, European Respiratory Society, Japanese Respiratory Society, Latin American Thoracic Society (ATS/ERS/JRS/ALAT), and the Fleischner Society each published guidelines for diagnosing IPF. These guidelines include criteria for four categories of confidence in a histologic usual interstitial pneumonia (UIP) pattern.

- **Objective**: To identify the role of the guidelines in the pathologic assessment of UIP; analyze the four guideline categories, including potential areas of difficulty; and determine steps that the Pulmonary Pathology Society and the greater pulmonary pathology community can take to improve guideline criteria and histopathologic diagnosis of interstitial lung disease.

- **Data sources**: Data were derived from the guidelines, published literature, and clinical experience.

- **Conclusions**: Both guidelines provide pathologists with tools to communicate to clinicians the likelihood that a biopsy represents UIP. They serve as an adjunct, not a replacement, for traditional histologic diagnosis. Multiple challenges exist with implementing the guidelines, including the lack of clarity on the quantity and quality of histologic findings required, the lack of recognition that histologic features cannot be assessed independently, and the lack of guidance on how pathologists should incorporate clinical and radiographic information. Criteria for "probable…

---

### Early diagnosis of fibrotic interstitial lung disease: challenges and opportunities [^115GQ9Kt]. The Lancet Respiratory Medicine (2021). Low credibility.

Many patients with interstitial lung disease (ILD) develop pulmonary fibrosis, which can lead to reduced quality of life and early mortality. Patients with fibrotic ILD often experience considerable diagnostic delay and are exposed to unnecessary and costly diagnostic procedures, as well as ineffective and potentially harmful treatments. Non-specific and insidious presenting symptoms, along with scarce knowledge of fibrotic ILD among primary care physicians and non-ILD experts, are some of the main causes of diagnostic delay.

Here, we outline and discuss the challenges facing both patients and physicians in making an early diagnosis of fibrotic ILD. We explore strategies to facilitate early identification of patients with fibrotic ILD, both in the general population and among individuals at highest risk of developing the disease. Finally, we discuss controversies and key uncertainties in screening programs for fibrotic ILD. Timely identification and accurate diagnosis of patients with fibrotic ILD pose several substantial clinical challenges but could potentially improve outcomes through the early initiation of appropriate management.

---

### An official ATS/ERS/JRS/ALAT clinical practice guideline: Treatment of idiopathic pulmonary fibrosis. An update of the 2011 clinical practice guideline [^111KDKff]. American Journal of Respiratory and Critical Care Medicine (2015). High credibility.

Regarding medical management for idiopathic pulmonary fibrosis, particularly concerning pirfenidone, the 2015 ALAT/ATS/ERS/JRS guidelines recommend initiating pirfenidone for the pharmacologic treatment of IPF.

---

### Diagnosis: To biopsy or not to biopsy: Assessing the role of surgical lung biopsy in the diagnosis of idiopathic pulmonary fibrosis [^113mypiN]. Chest (2005). Low credibility.

Idiopathic pulmonary fibrosis (IPF) is a chronic disorder with a poorer prognosis compared to subacute idiopathic interstitial pneumonias (IIPs). IPF can be differentiated from other IIPs by its histologic pattern of usual interstitial pneumonia (UIP). A surgical lung biopsy specimen showing a UIP pattern is necessary for a definitive diagnosis of IPF. However, in the absence of a lung biopsy specimen, clinical criteria can be utilized to make a likely diagnosis of IPF.

The predictive value of these criteria largely depends on the clinician's and radiologist's expertise. Nonetheless, considerable interobserver variability exists even among field experts. These criteria lead to misdiagnosis in approximately 25 to 35% of cases. The interobserver variability decreases, and diagnostic accuracy improves when a diagnosis is made with a high degree of confidence. Furthermore, diagnostic accuracy is higher when made by a core group of experts rather than a referring center. The decision to perform a surgical lung biopsy remains challenging and is clearly indicated in cases where clinical or radiologic findings are atypical or when the diagnosis is made with a low degree of certainty.

---

### Idiopathic pulmonary fibrosis (an update) and progressive pulmonary fibrosis in adults: An official ATS/ERS/JRS/ALAT clinical practice guideline [^111WQgqx]. American Journal of Respiratory and Critical Care Medicine (2022). High credibility.

Radiological features of UIP, the hallmark of idiopathic pulmonary fibrosis (IPF), were described in detail in the 2018 guidelines for the diagnosis of IPF. The guideline committee concluded that several radiological features warrant reiteration in the guideline for emphasis, and they reconsidered the categories of high-resolution computed tomography (HRCT) patterns.

- **Spectrum of HRCT findings in IPF**: Lung fibrosis is confidently recognized when traction bronchiectasis/bronchiolectasis and/or honeycombing are identified, although honeycombing must be distinguished from paraseptal emphysema and airspace enlargement with fibrosis. Pathologic–computed tomography correlations have demonstrated that honeycombing and traction bronchiolectasis are closely related. Honeycombing corresponds to bronchiolar cysts, developed after collapse of fibrotic alveolar septa and dilatation of terminal airways. The cystic structures sometimes can be followed throughout the lobular core, seem to be connected with each other, and are in continuity with the bronchial tree. Honeycombing cysts consist of both dilatation of peripheral airspaces due to surrounding alveolar septal fibrosis and tangentially viewed traction bronchiolectasis. HRCT findings typical of usual interstitial pneumonia (UIP) and honeycombing on HRCT correlate best with bronchiolectasis histologically. Recent observations have underlined that in IPF, the remodeling process appears to be a continuum from traction bronchiectasis to honeycombing.

---

### Idiopathic pulmonary fibrosis: Current and future directions [^113sj3zJ]. Clinical Radiology (2017). Low credibility.

Idiopathic pulmonary fibrosis (IPF) is the most common idiopathic interstitial pneumonia and is increasingly recognized. Prior to the advent of effective therapies, achieving an early diagnosis was of little prognostic consequence, as IPF was considered an untreatable and uniformly fatal disease. The advent of new drug treatments has provided hope for the future and has raised the profile of IPF.

International management guidelines highlight the critical role of radiology as part of an interstitial lung disease multidisciplinary team approach in reaching an accurate and early diagnosis of IPF. The diagnostic criteria and levels of diagnostic confidence for the radiopathological pattern associated with the clinical syndrome of IPF, usual interstitial pneumonia (UIP), appear straightforward. However, with increasing research and recognition of radiopathological interobserver variability, limitations of this classification model are becoming increasingly apparent.

This review describes ancillary radiological features, comorbidities, and emerging new entities that potentially coexist with IPF. Beyond diagnosis, radiology is developing as a key prognostic tool to inform longitudinal patient evaluation. These diagnostic and prognostic clinical challenges, along with the future role of radiology in IPF, are discussed.

---

### Idiopathic pulmonary fibrosis: Challenges and opportunities for the clinician and investigator [^113j4BJJ]. Chest (2005). Low credibility.

Idiopathic pulmonary fibrosis (IPF) is a relentlessly progressive and typically fatal interstitial lung disease. Besides its grave natural history and prognosis, three aspects of IPF challenge clinicians and investigators:

- **Recent changes in conceptual framework and definition**: These changes complicate the interpretation of prior clinical investigations.
- **Lack of validated clinical definitions without biopsy criteria**: Most patients with suspected IPF do not undergo an open-lung biopsy. Clinical definitions that do not include biopsy criteria have not been validated prospectively.
- **Ineffectiveness of available treatments**: Current treatments have not been shown to be effective.

To optimize clinical care and facilitate clinical investigation, a major goal of IPF research should be to develop validated sets of clinical diagnostic and prognostic criteria. Studies have demonstrated the diagnostic value of high-resolution CT scans and identified important prognostic variables; however, many of these observations await prospective validation.

While previous therapeutic studies have been limited by small sample sizes, lack of a placebo control group, and insufficient attention to patient-centered outcomes, the recent study of interferon gamma-1b demonstrated the feasibility of conducting a large-scale, multicenter clinical trial in IPF. In this article, we discuss how overcoming challenges in IPF research will enable future investigators to conduct well-designed observational studies and clinical trials. These meaningful results will advance our understanding of IPF, its management, and its impact on patients' lives.

---

### Approach to the evaluation and management of interstitial lung abnormalities: An official American Thoracic Society clinical statement [^116YtoiG]. American Journal of Respiratory and Critical Care Medicine (2025). Low credibility.

Conclusions

Tertiary prevention strategies that focus on established pulmonary fibrosis have had limited impact on the morbidity and mortality associated with ILD. Identifying individuals before the onset of clinically evident lung fibrosis (i.e. when findings qualify as ILA) provides an opportunity to intervene before the lung is extensively and irreversibly scarred (i.e. primary and secondary prevention) if effective and well-tolerated treatments can be identified. This document presents a comprehensive literature review of ILAs that supports updates to the previous ILA definition made by the Fleischner Society, establishes a working definition of ILD, and provides evidence-based suggestions for the evaluation and management of ILAs. Together, these advances will improve clinical care and support future research by standardizing the approach to ILAs.

In addition, this document highlights important unanswered questions, providing direction for future initiatives while emphasizing the need to identify treatment options for ILA.

---

### An official ATS/ERS/JRS/ALAT statement: Idiopathic pulmonary fibrosis: Evidence-based guidelines for diagnosis and management [^111KFZ9s]. American Journal of Respiratory and Critical Care Medicine (2011). High credibility.

Regarding the screening and diagnosis of idiopathic pulmonary fibrosis, the ALAT/ATS/ERS/JRS 2011 guidelines specifically recommend not using the major and minor criteria proposed in the 2000 ATS/ERS Consensus Statement.

---

### Patient registries in idiopathic pulmonary fibrosis [^114VtB7Z]. American Journal of Respiratory and Critical Care Medicine (2019). Low credibility.

Registries are perhaps the most important source of data on practices in the diagnosis of IPF and ultimately allow evaluation of temporal trends in diagnostic procedures. For example, surgical lung biopsies have been performed in 13–35% of patients enrolled in registries. In eurIPFreg, 20–30% of patients diagnosed with IPF in 2010–2011 had open or thoracoscopic lung biopsy, but these numbers declined in the following years.

- **Bronchoscopy and BAL fluid analysis**: Rates vary widely across registries, with analysis of BAL fluid conducted in 85% of patients in eurIPFreg and 62% of patients in INSIGHTS-IPF. Bronchoscopy was performed in only about 20% of patients in the Australian IPF Registry and an even smaller proportion in the IPF-PRO Registry.

- **Multidisciplinary discussion (MDD)**: Data from the INSIGHTS-IPF, Pulmonary Fibrosis Foundation, and IPF-PRO registries suggest that MDD was performed at the enrolling center in 22%, 40%, and 42% of patients, respectively. It is unclear to what extent diagnoses made without MDD reflect clinicians' belief that MDD was not required to make a diagnosis of IPF in a particular patient, rather than a lack of access to a multidisciplinary team. In the Australian IPF Registry, a central multidisciplinary review was implemented to overcome the paucity of local access to MDD. There is no standard definition of MDD in the diagnosis of IPF, and different sites/registries may have interpreted "MDD" in very different ways.

Interestingly, recent data from the Australian IPF Registry…

---

### Diagnosis and management of idiopathic pulmonary fibrosis: Implications for respiratory care [^116KddEp]. Respiratory Care (2006). Low credibility.

Idiopathic pulmonary fibrosis, though poorly understood, is the most common of the idiopathic interstitial lung diseases. Its etiology remains unknown, but the development of this fibrotic process in the lungs has been studied over the past 60 years. It is a relatively rare disease, affecting individuals aged 50 to 70, and is slightly more prevalent in men than in women, without racial predilection.

The most common symptom is progressive shortness of breath. Pulmonary function testing often reveals a restrictive ventilatory defect with diminished diffusion capacity. Radiographic and pathologic examinations show fibrotic and cystic areas interspersed with normal lung tissue.

- **Treatment**: Currently, there is no definitive medical treatment available. However, most patients are given trials of corticosteroids, either alone or in combination with cytotoxic agents.
- **Prognosis**: On average, patients survive two to four years after diagnosis. Lung transplantation is the only therapy shown to improve survival for those with idiopathic pulmonary fibrosis.

---

### Critical reappraisal of underlying histological patterns in patients with suspected idiopathic pulmonary fibrosis [^115NbEeN]. Current Opinion in Pulmonary Medicine (2019). Low credibility.

The usual interstitial pneumonia (UIP) pattern is the histologic marker of idiopathic pulmonary fibrosis (IPF); however, the usefulness of ancillary histologic findings may discriminate idiopathic from secondary UIP.

Recent findings suggest that alternative, less invasive procedures may identify the UIP pattern, thereby preventing the necessity for conventional surgical lung biopsy. Genomic analysis may also recognize the UIP pattern from otherwise poorly diagnostic samples.

High-resolution computed tomography identifies a 'definite' UIP pattern in about half of cases, yet it may fail to recognize UIP in the absence of honeycombing or in limited disease. Although there is a need to redefine the radiologic criteria for UIP to improve diagnostic yield, the histologic features of UIP have not significantly changed since the 1960s. They continue to represent a major diagnostic tool, particularly in challenging interstitial lung diseases. Careful recognition of certain histologic ancillary findings in UIP, such as cellular/follicular bronchiolitis with germinal centers, chronic pleuritis, interstitial granulomas/giant cells, and bridging fibrosis, may be helpful in distinguishing secondary forms (e.g. connective tissue disease, chronic hypersensitivity pneumonia) from IPF.

Cryobiopsy and awake-biopsy are promising approaches to obtain representative lung tissue, potentially preventing conventional surgical lung biopsy. Genomic techniques have recently demonstrated good-to-high sensitivity and specificity in disclosing the UIP pattern by using RNA obtained in transbronchial biopsy, possibly replacing and/or complementing traditional histology soon.

---

### The 2018 diagnosis of idiopathic pulmonary fibrosis guidelines: Surgical lung biopsy for radiological pattern of probable usual interstitial pneumonia is not mandatory [^115Jtz5k]. American Journal of Respiratory and Critical Care Medicine (2019). Low credibility.

The radiological patterns of usual interstitial pneumonia (UIP) described in the ATS/ERS/JRS/ALAT guidelines are similar to those described in a statement from the Fleischner Society; however, the two documents make seemingly different recommendations about whether to perform surgical lung biopsy (SLB) in patients with the radiological probable UIP pattern by high-resolution computed tomography (HRCT). Specifically, the ATS/ERS/JRS/ALAT guidelines make a conditional recommendation for SLB after multidisciplinary discussions (MDDs), whereas the Fleischner Society statement indicates that a confident diagnosis of IPF can be made without SLB in the right clinical context. This reflects differences in methodology and terminology rather than any substantive difference in principles and recommended practices.

It is apparent that the recommendations in the ATS/ERS/JRS/ALAT guidelines are subject to misinterpretation as a mandate for SLB in patients with probable UIP. Avoiding this misinterpretation is precisely why the ATS/ERS/JRS/ALAT recommendation was assigned a strength of "conditional" (Table 1), a grading option that was not available to the authors of the Fleischner Society statement. A conditional recommendation conveys that the course of action is appropriate for most patients but may not be appropriate for a sizeable minority of patients. The guideline panel anticipated that among patients who meet HRCT criteria for probable UIP, there will be a spectrum of suspicion for IPF ranging from high to low depending on the clinical context.

---

### An official ATS/ERS/JRS/ALAT statement: Idiopathic pulmonary fibrosis: Evidence-based guidelines for diagnosis and management [^113PoyTn]. American Journal of Respiratory and Critical Care Medicine (2011). High credibility.

Regarding nonpharmacologic interventions for idiopathic pulmonary fibrosis, more specifically with respect to pulmonary rehabilitation, ALAT/ATS/ERS/JRS 2011 guidelines recommend considering offering pulmonary rehabilitation to the majority of patients with IPF.

---

### Re-evaluation of diagnostic parameters is crucial for obtaining accurate data on idiopathic pulmonary fibrosis [^111Yyx45]. BMC Pulmonary Medicine (2015). Low credibility.

In order to systematically evaluate the nationwide prevalence of idiopathic pulmonary fibrosis (IPF) in different geographical areas, we narrowed the study population to five university hospital cities and their populations at the end of the year 2012. The university hospitals represent tertiary hospitals, the most specialized level of public health care. All IPF patients who gave informed consent and lived during 2012 in the university hospital cities of Helsinki, Turku, Tampere, Kuopio, or Oulu (see Fig. 1 for geographical location) were included. In Finland, patients are referred to specialist centers according to their living address, and practically all IPF patients are initially evaluated within the public health care system.

- **Geographical data**: The geographical location and areas of the five university hospital cities in Finland, where the cohort was collected, demonstrate that their population was 1.29 million, representing 24% of the total population in Finland.

The patient registries of the five university hospitals were screened for the ICD-10 diagnosis codes J84.1 (other interstitial pulmonary diseases with fibrosis) and J84.9 (interstitial pulmonary disease). The diagnostic criteria of the ATS/ERS statement 2011 were used. An experienced pulmonary physician re-evaluated the patients' data by thoroughly reviewing the patient charts. It was found that 70–80% of patients' diagnoses did not meet the clinical criteria for idiopathic pulmonary fibrosis. The disqualified cases were other idiopathic interstitial pneumonias (IIP), most commonly non-specific interstitial pneumonias (NSIPs).

---

### Idiopathic pulmonary fibrosis - clinical management guided by the evidence-based GRADE approach: what arguments can be made against transparency in guideline development [^113ckTe9]. BMC Medicine (2016). Low credibility.

Evidence-based guidelines have undergone an incredible transformation over the last number of years. Significant advances include explicit linkages of systematic evidence summaries to the strength and direction of recommendations, consideration of all patient-important factors, and transparent reporting of the recommendation generation process, including conflict of interest management strategies. The production of clinical practice guidelines now uses simple and clear language.

The Grading of Recommendations Assessment, Development and Evaluation (GRADE) methodology provides a framework for guideline development and was employed to produce the recently published ATS/ERS/JRS/ALAT update on treatment for idiopathic pulmonary fibrosis (IPF). Here, we discuss the advantages of using an evidence-based approach for guideline development, using the IPF process and resultant document as an example.

---

### Diagnosis of idiopathic pulmonary fibrosis. An official ATS/ERS/JRS/ALAT clinical practice guideline [^115k7VK8]. American Journal of Respiratory and Critical Care Medicine (2018). High credibility.

Regarding the medical management of idiopathic pulmonary fibrosis, specifically in terms of general principles, the ALAT/ATS/ERS/JRS 2018 guidelines recommend ensuring a multidisciplinary discussion for diagnostic decision-making in patients with IPF.

---

### What causes cough in pulmonary fibrosis, and how should we treat it [^113rqQ5N]. Current Opinion in Pulmonary Medicine (2024). High credibility.

- **Background**: Pulmonary fibrosis is a chronic lung disease characterized by progressive scarring of lung tissue, which can lead to a persistent cough.
- **Pathophysiology**: Understanding the pathophysiology of cough in pulmonary fibrosis is crucial for effective management. Increased sensitivity of cough receptors and fibrotic changes in lung tissue contribute significantly.
- **Treatment strategies**: Effective treatment to alleviate cough in pulmonary fibrosis includes both pharmacological and non-pharmacological approaches. Current pharmacological options include medications like anti-fibrotic agents and neuromodulators, whereas non-pharmacological strategies focus on patient education and pulmonary rehabilitation. Further research is needed to explore novel therapeutic targets and improve patient outcomes in this area.

---

### The revised ATS/ERS/JRS/ALAT diagnostic criteria for idiopathic pulmonary fibrosis (IPF) — practical implications [^112mQBaa]. Respiratory Research (2013). Low credibility.

A deficiency common to all guideline statements is the absence of pragmatic guidance on the level of risk of SLB in individual patients. A clearer separation between patients who can undergo an SLB with an acceptably low risk and those in whom SLB should be avoided would be helpful to clinicians. The presence of major comorbidity is an obvious contraindication to SLB, but the level of severity of IPF associated with a significant increase in postoperative mortality has not been sufficiently addressed.

It is acknowledged that in the absence of definitive data, broad statements based on indirect evidence might be required. However, guidance on this point, even if based solely on expert opinion, would be extremely useful as a means of facilitating patient participation in decisions based on "risk-benefit" thinking.